Indiana Reaches $6.25 Million Settlement in EpiPen Price-Fixing Case

Attorney General Todd Rokita said the agreement resolves claims that Viatris Inc., Pfizer Inc., and other companies engaged in coordinated actions that significantly increased the cost of the life-saving allergy medication. Per a statement from the attorney general’s office, the companies were accused of raising EpiPen prices by more than 600 percent over time.

We’d love to be your preferred source for news.

Please add us to your preferred sources list so our news, data and interviews show up in your feed. Thanks!

Add as Preferred Source

The settlement stems from allegations that the pharmaceutical firms conspired to inflate prices, placing a financial burden on consumers who rely on the emergency treatment for severe allergic reactions. According to a statement, state officials argued that the pricing practices unfairly impacted Indiana families and healthcare providers.

Rokita maintained that the legal action was aimed at holding corporations accountable for what the state described as excessive price hikes. Per a statement, the attorney general’s office asserted that the settlement reflects Indiana’s commitment to protecting consumers from anti-competitive conduct in the pharmaceutical market.

Related: Mylan Agrees to $73.5 Million Settlement Over EpiPen Pricing Allegations

The $6.25 million agreement concludes Indiana’s claims related to the alleged coordination among the companies. According to a statement, the funds secured through the settlement are intended to address the harm caused by the dramatic price increases.

Viatris Inc., Pfizer Inc., and other companies named in the case were accused of participating in the alleged scheme, though the settlement resolves the matter without further litigation. Per a statement from state officials, the outcome underscores ongoing efforts to scrutinize pricing practices within the pharmaceutical industry.

Source: WTHR